Categoría: Medication
Etiquetas: #covid19 #studies #mentalhealth #treatment
More content you may find interesting
Chloroquine and hydroxychloroquine are well-known treatments for their use in the treatment and prevention of malaria, but lately, they have been in the spotlight due to their recent use in emergency cases of severe COVID-19 infections.
It is widely known that these drugs can produce cardiac, renal, and ophthalmological alterations. However, their effects on neuropsychiatric levels are not known with certainty.
A 12% incidence of neuropsychiatric disorders has been reported with the use of these drugs (specifically amnesia, delirium, hallucinations, memory loss, and loss of consciousness). These symptoms tend to appear at the beginning of treatment and seem to be independent of the doses used.
Nevertheless, it is not clear whether these symptoms are due to the drugs themselves or to the COVID-19 disease itself, which, as I explained in a previous article, can also produce similar symptoms.
High-quality randomized clinical trials are needed to determine whether there is a causal relationship or not, and as of today, we do not have them.
However, the FDA revoked its recommendation for the use of these drugs in emergencies for the treatment of COVID-19 on June 15, 2020.
Article by psychiatrist Dr. Paula Moreno on the use of Chloroquine in COVID-19 and its relationship with neuropsychiatric disorders.